仁和藥業(000650.SZ):子公司格列齊特緩釋片通過一致性評價
格隆匯5月9日丨仁和藥業(000650.SZ)公佈,近日,公司下屬子公司江西製藥有限責任公司收到國家藥監局核准簽發的關於格列齊特緩釋片的《藥品補充申請批件》,該藥品通過仿製藥質量和療效一致性評價。
格列齊特緩釋片(Gliclazide Modified Release Tablets)為第二代磺酰脲類藥物,用作口服糖尿病治療藥物,主治用於當單用飲食療法不足以控制血糖的非胰島依賴型糖尿病,其降血糖強度介於甲磺丁脲和優降糖之間。
該品種原研廠家為法國的Les Laboratoires Servier,商品名為Diamicron,規格:30mg、60mg,最早上市時間為2000年3月29日,上市國家包括法國、德國、英國等國。公司該產品2021年銷售收入2772.86萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.